Could Phinomics’ circular DNA platform expose the blind spots slowing cancer drug development?
Find out how Phinomics is using circular DNA and explainable AI to reshape oncology discovery and cancer biomarker research.
Pharma & Biotech
Pharma & Biotech
Is botensilimab finally ready for a bigger melanoma spotlight? Agenus bets on ASCO 2026
Agenus will unveil first Phase 2 botensilimab melanoma data at ASCO 2026. Read why the update could reshape sentiment around its checkpoint platform.
Pharma & Biotech
What Agenus’ BOT and BAL biomarker work reveals about rescuing immunologically cold tumors
Agenus’ AACR-IO biomarker data reframes inflammation as a key determinant in cold tumor immunotherapy. Find out why this could reshape checkpoint strategies.